novartis semaglutide STAT Readout Newsletter: Today's biggest biotech updates Novo Nordisk medicines containing semaglutide

Priced at $625 million, it was already the largest US biotech listing since 2021, eclipsing Modernas then-record $604 million IPO from 2018

Weight regain following GLP-1RA discontinuation is common and often rapid, indicating that pharmacological appetite suppression does not permanently reset biological weight-defense systems ( Postbiotics introduce a contrasting paradigm

Tesamorelin: The Visceral Fat Specialist Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that is FDA-approved for the reduction of excess abdominal visceral fat in HIV-positive patients with lipodystrophy

Vesoria delivers triple support in one formulaappetite balance, metabolic support, and gut healthwithout harsh stimulants, making it easier to use consistently every day